NewAmsterdam triumphs in first Phase III trial of cholesterol-busting drug
NewAmsterdam Pharma announced a win in the first of its four Phase III, pivotal trials, showing its lead cardio candidate obicetrapib can reduce cholesterol levels. The BROOKLYN trial (NCT05425745) is the first of four studies in NewAmsterdam’s portfolio …